To evaluate the efficacy of a combined treatment with Cilengitide and metronomic oral Temozolomide in children and adolescents with relapsed or refractory high-grade malignant glioma and diffuse intrinsic pontine glioma as indicated by 6 months overall survival OS after diagnosis of relapse or tumour progression in comparison to a historical control group of paediatric HGG relapse patients from the HIT-GBMHIT-HGG data base
Data and Resources
- Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Studyjson
To evaluate the efficacy of a combined treatment with Cilengitide and...
|Release Date|| |
|Public Access Level|| |